A Hybrid Cellular Automata Model for the Role of Reactive Oxygen Species in Novel Tumour Treatments Strategies by May, Brandon
  
 
 
 
A Hybrid Cellular Automata Model for the 
Role of Reactive Oxygen Species in Novel 
Tumour Treatments Strategies 
 
 
by 
Brandon May 
 
 
 
A thesis 
presented to the University of Waterloo 
 in fulfillment of the 
thesis requirement for the degree of  
Master of Mathematics 
in 
 Applied Mathematics 
 
 
Waterloo, Ontario, Canada, 2015 
© Brandon May 2015 
ii 
 
I hereby declare that I am the sole author of this thesis. This is a true copy of the thesis, 
including any required final revisions, as accepted by my examiners. 
I understand that my thesis may be made electronically available to the public. 
  
iii 
 
 
 
 
 
Abstract 
Cancer is a disease that entails uncontrolled proliferation and a disruption of 
tissue function that often results in a poor clinical outcome. Furthermore, it 
has continued to elude any universal treatment or cure in part because of the 
complexity seen across multiple spatial and temporal scales. In silico 
modelling techniques, such as hybrid cellular automata (HCA), provide an 
inexpensive and versatile means of incorporating experimental factors that 
are either impossible or infeasible to control and investigate when using in 
vivo or in vivo experimental settings. Reactive oxygen species (ROS) are 
critical molecules in cellular processes and have been demonstrated to induce 
effects on cellular processes ranging from proliferation to metabolic 
reprogramming and cell death. Dichloroacetate (DCA) and intravenous 
vitamin C (VC) are two proposed treatments that induce death via ROS and 
have begun to gain attention from the oncology community for their relative 
lack of toxicity and potential efficacy. Thus, investigating a HCA model to 
optimize their effects can be influential in the success of these drugs. The 
model employed uses discrete rules for the evolution of each cell, and 
continuous equations for diffusible elements so that multiple time scales may 
be incorporated effectively. The implementation of components such as 
necrotic cell removal and accurate pharmacokinetics in the model has a 
considerable effect on outcome of VC treatment individually and in 
combination. Furthermore, VC is most effective at removing tumour cells 
entirely when its plasma concentration is maximized, while DCA’s cytotoxic 
action plateaus as its concentration increases and is only effective at 
removing cell types that exist within the interior of the tumour. 
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Chapter 1 
Biological Background 
1.1 Introduction 
Despite improving the overall quality of health and life expectancy, modern medicine 
has been unable yet to counter the detrimental effects of cancer. Rather than elucidating a 
concise cause and mechanism of action in the progression of cancer, decades of research 
have revealed the complexity underlying the disease. Simply stated, cancer is the result of 
uncontrolled cell proliferation. Unfortunately, the manner in which it presents itself varies 
significantly among those afflicted. This is in part due to the vast array of genetic, epigenetic 
and environmental factors that can result in sustained cell division [Feinberg and Tycko 
2004, Hanahan and Weinberg 2011]. Since these factors may accumulate over a timespan on 
the scale of years, focusing instead on the properties which enable the survival and success 
of various cancerous phenotypes is a promising approach to understanding the disease and 
implementing effective treatments. To illustrate, there are many possible genes that can 
promote proliferation (i.e., proto-oncogenes) or prevent the appropriate arrest of cell cycle 
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processes (i.e., tumour suppressor genes). However, mutations in these genes can have 
elaborate effects on the outcome of a cell through their role individually and also in 
conjunction with others. These effects are further diversified by the timing of when the 
normal function of these genes is disrupted. Since a single mutation is not sufficient for the 
development of malignant disease, the frequency of tumourigenic mutations, and not just the 
specificity, has been illustrated to be correlated with incidences of cancer [Croce 2008, 
Weinberg 2007]. 
Approaches in understanding the disease have revealed models in which the 
environment of a tumour plays a critical role in regulating the progression of cancer. 
Through a number of mechanisms explained later in this section, cells that make up a tumour 
are able to take advantage of the hostile environment that results from their formation. In 
particular, the environment varies in distribution of blood vessels, oxygen concentration and 
pH profile. It is the limited viability of this environment that is thought to provide the 
selective pressures driving the emergence of phenotypes of varying aggressiveness 
[Anderson et al. 2006, Molavian et al. 2009, Smallbone et al. 2007]. As a result, the growth 
dynamics of the tumour will be the result of its adaption to the environment. Despite the 
large and intricate nature of the signalling networks governing growth, mitosis, cell death, 
inflammation, and vascularization, the progression of tumour cells to an invasive phenotype 
has an intimate link with the composition of the microenvironment.  
One method of cellular signalling that has received increasing attention in oncology 
research is via reactive oxygen species (ROS).  While it has been well established that ROS 
are crucial in sustaining operation of the electron transport chain, recent evidence has 
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revealed a far more elaborate role. Aside from their toxic potential, ROS have been 
discovered to act as messenger molecules within transformed cells. While the range of 
effects vary from metabolic restructuring to division to programmed cell death, the actual 
network and interactions involved have not yet been fully explained [Behrend et al. 2003, 
Irani et al. 1997, Schimmel and Bauer 2002, Suh et al. 1999]. Nevertheless, the key proteins 
regulating the hypoxic response have been catalogued and shown to be stabilized by 
mitochondria-derived ROS [Chandel et al. 2000, Hamanaka and Chandel 2010]. Since 
cancer cells have often been observed to express increased concentrations of intracellular 
oxidants, the dynamics between ROS-induced metabolic reprogramming and cell death will 
be of particular interest herein [Trachootham et al. 2009].  
As with all novel scientific discoveries in cancer research, potential treatment 
strategies have been proposed to disrupt the signals favouring growth for the cancer cells in 
the relationship. It is interesting to note that both anti-oxidant and pro-oxidant therapies have 
been investigated, but pro-oxidant theories will be investigated herein.  
Two drugs of interest are ascorbate, or vitamin C (VC), and dichloroacetate (DCA) 
because of their intriguing effects on the microenvironment and phenotypic composition of 
tumours. Although VC has been described as being an anti-oxidant in physiological 
concentrations, blood concentrations achievable only by intravenous infusion have been 
demonstrated to induce the formation of the ROS, hydrogen peroxide (H2O2) [Chen et al. 
2007]. Because of their toxic potential, intracellular ROS levels are maintained using anti-
oxidant mechanisms. Since most tumour cells have consistently higher levels of ROS, it is 
reasonable to assume they are less apt than normal cells at surviving exogenous ROS stress, 
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as depicted in figure 1.1 [Trachootham et al. 2009, Wartenberg et al. 2003]. The reasoning is 
that antioxidant mechanisms are under more basal stress and cannot compensate for the 
increase. Thus, administering pro-oxidant drugs has been proposed as a possible treatment 
strategy that would cause little or no permanent damage to healthy tissues. Similar to VC, 
DCA has been used for decades for medicinal purposes but has only recently been 
recognized for its potential benefits in cancer [Michelakis et al. 2008]. Originally intended 
for the treatment of congenital lactic acidosis, DCA restores aerobic metabolism in cells with 
mitochondrial deficiencies [Stacpoole 1998]. Michelakis and his colleagues found that in 
addition to restoring metabolic structure of the mitochondria, a cascade of effects promoting 
cell death also occurred. For these reasons, DCA is currently in Phase II clinical testing for 
assessment in cancer treatment [Michelakis et al. 2008, Michelakis et al. 2010].  
 
 
 
 
 
 
However, these drugs have already been approved for use in medical settings not involving 
cancer and with little or no toxic side effects; thus, they have been administrated by 
 
Lethal ROS Threshold 
Endogenous 
Production 
Externally 
Sourced 
Figure 1.1: Rationalization for pro-oxidant treatment strategies. Adapted from 
[Trachootham et al. 2009]. 
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alternative health care specialists already [Padayatty et al. 2010]. As a result, there is a 
current need to maximize the response of the tumour to the treatment through detailing how 
to optimize schedules. In this thesis, previously explored models used to describe tumour 
metabolism are expanded to incorporate ROS-based treatments. Novel treatment strategies 
using realistic pharmacokinetics and combining both DCA and VC are investigated using 
tumours that are responsive to the effects ROS on metabolism and cell death. This reveals 
the underlying optimal strategies and tumour behaviour that results from each treatment. 
However, before attempting to create the model to do so, a thorough explanation of the 
relevant biological processes is necessary. 
 
1.2 The Progression of Tumour Formation 
 1.2.1 Introduction to Cancer  
 One of the significant challenges presented in studying cancer is the large diversity of 
diseases through which it presents itself [Hanahan and Weinberg 2000]. For this reason, 
understanding what factors drive the progression from a normal cell to one with a high 
proliferation rate to one that is capable of invading other tissues is the focus of much 
research. Metastasis, the formation of tumours at secondary sites from invasive cells of the 
original tumour, are frequently observed and associated with poor prognoses. Similarly, 
acquired drug resistance is a trait observed to arise late in treatment. Thus, improving 
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clinical outcome necessitates a detailed understanding of the factors driving phenotypic 
evolution. 
Cancer can be first initiated by a mutation in any of the genes responsible for 
regulating DNA repair or the cell cycle and death. However, it does not usually progress to a 
stage that can be diagnosed until there have been multiple mutations acquired. For instance, 
the number of genomic instability events observed in colorectal cancers was measured to be 
greater than 104 [Stoler et al. 1999]. Nevertheless, there is a set of characteristics that is 
observed almost universally in cells at some point or another in the progression from 
normalcy to malignancy; these have been dubbed the hallmarks of cancer [Hanahan and 
Weinberg 2000, Hanahan and Weinberg, 2011]. It is these defining characteristics that allow 
researchers to observe and discuss the intricate behaviour of tumours through a 
compartmentalized set of properties. 
1.2.2 Promoting Growth While Evading Death 
The most fundamental phenotypic change acquired by cells during tumour 
pathogenesis is the ability to promote proliferation through self-sustaining signals [Hanahan 
and Weinberg 2011]. During the normal formation of tissues and wound healing, a cell will 
begin and progress through the cell cycle only when growth-promoting signals are sustained. 
The signalling molecules are secreted by neighbouring tissues and are most often processed 
through the family of cell membrane-spanning proteins, receptor tyrosine kinases (RTK). 
Because of the difficulty in empirically measuring the paracrine-like signalling involved 
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Figure 1.2: The hallmarks of cancer, including the emerging concepts and enabling 
characteristics described in [Hanahan and Weinberg 2011]. 
between tissues in vivo, there is relatively little known on the pathways driving proliferative 
signalling in normal tissues. In contrast, much more is known about this process in 
 
 
 
 
 
 
 
 
malignant tissues [Hanahan and Weinberg 2011]. For instance, there have been numerous 
mechanisms observed through which cancerous tissues are able maintain self-sufficient 
proliferative signalling. This can be accomplished through increased secretion or expression 
of either the ligand or the corresponding receptor by the cancer cell. Alternatively, they may 
recruit aid from normal cells in the surrounding tissues by initiating their release of growth 
stimulating factors [Cheng et al. 2008, Bhowmick et al. 2004]. To illustrate further, one of 
the most common mutations present in human cancers is in the signalling mediator, Ras. 
Cells may possess a mutant form of this receptor that is active without stimulation by growth 
Hallmarks of Cancer 
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factors, or alternatively, a mutant form of any of the downstream proteins in the signalling 
pathway [Hanahan and Weinberg 2011]. However, these mechanisms alone are not 
sufficient to maintain rapid growth. 
To prevent uncontrolled growth, normal tissues have a number of control 
mechanisms that operate on a variety of aspects of the cell cycle. When proliferative 
signalling pathways like those mentioned above are stimulated, negative feedback 
mechanisms are often in place to gradually dampen the effect of the signal. However, the 
proteins responsible for this homeostatic response are not always functioning in cancer. With 
respect to the Ras signalling pathway, it is the protein GTPase that is responsible for 
ensuring that proliferative signals are transitory [Weinberg 2007]. It is important to note that 
when the intrinsic signalling mechanisms are faulty and over-promote growth, it is not 
guaranteed that the cell will continue to divide indefinitely. Senescence and apoptosis have 
been observed following the excessive stimulation of signalling pathways through proteins 
such as Myc, Ras, and Raf. [Collado and Serrano 2010, Evan and d’Adda di Fagagna 2009, 
Lowe et al. 2004]. Thus, in order to establish neoplastic disease, cells must evade the 
regulatory mechanisms employed during cell cycle events. 
The mechanisms utilized by healthy cells to ensure the proper progression of mitotic 
and cell cycle events are understandably thorough [Hanahan and Weinberg, 2011]. By 
having a controlled response to both the intracellular and extracellular factors affecting 
mitosis and survival, the collective fitness of the cells can be maximized. The canonical 
tumour suppressor proteins discussed in cancer research are Rb and p53. The Rb protein acts 
as a gatekeeper for cell-cycle progression. As such, division may only occur in the absence 
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of exogenous growth-inhibitory signals. In contrast, p53 is responsive to the intracellular 
factors that may result in a decreased survival probability. Specifically, this includes damage 
to the genome and low levels of nucleotide pools, glucose or oxygen. Rather than simply 
arresting the cell cycle and preventing division, p53 is able to induce programmed cell death 
that results in the attenuation of mutations [Weinberg and Hanahan 2011]. Interestingly, cell 
homeostasis is not immediately affected by a loss of normal function of either tumour 
suppressor or proto-oncogenes individually and neoplastic effects do not result until later in 
life [Lipinksi and Jacks 2010, Ghebranious and Donehower 1998]. This further supports the 
notion that malignant diseases are the result of many acquired mutations.  
In addition to the explicit signalling pathways that regulate cell cycle progression, 
there are other mechanisms in place that ensure the proper formation and maintenance of 
tissues. One of the most essential traits acquired in a tumour’s evolution to malignancy is the 
ability to evade contact inhibition and gain anchorage-independence [Smallbone et al. 2007]. 
In epithelial tissues, cells are joined together in single layers by a series of junctions that 
serve a variety of signalling, transport, and structural purposes [Lodish 2008]. Recent 
literature has revealed the role of two proteins, Merlin and LKB-1, in promoting epithelial 
integrity.  Merlin, for example, accomplishes this task by coupling RTK’s to the proteins that 
maintain the junction, effectively decreasing their ability to respond to signals in the 
environment [Hanahan and Weinberg 2011, Curto et al. 2007, Okada et al. 2005]. 
Conversely, although LKB-1 has been found to promote cell polarity and the formation of 
cell junctions, the exact protein interactions responsible for the response are yet unknown. 
Nonetheless, the presence of a mutated form of LKB-1 has been shown to promote a 
phenotype that is conducive to invasive growths [Partanen et al. 2012].  When these 
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mechanisms are not in place, and thus the cell is not anchored to its adjacent neighbours or 
the extracellular matrix (ECM), a programmed form of cell death, anoikis, usually results 
[Weinberg 2007].  Even when these properties are possessed by a cell, this does not confer 
immortality. This is due to the inevitable loss of genetic material at the ends of chromosomes 
after each division. This region of a chromosome is known as a telomere and consists of 
multiple tandem repeats that are often truncated after each division. Incidentally, a cell that 
is dividing rapidly will quickly lose the stability of its genome as chromosome ends begin to 
fuse [Hanahan and Weinberg 2011]. Clearly, this presents a hurdle that must be overcome in 
the progression of a malignant disease. Telomerase is a DNA-binding protein that specializes 
in extending the telomeric regions of DNA. In doing so, unlimited replicative potential is 
incurred to the cell [Blasco 2005]. Although increasing the expression of telomerase early in 
tumour formation is expected to accelerate the process, genetic damage consistent with 
telomere-shortening has been observed in a number of tumours prior to acquiring 
malignancy [Raynaud et al. 2010, Chin et al. 2004]. Thus, it has been proposed that the 
mutations acquired following telomere-shortening events may actually contribute to the 
tumour-promoting potential [Hanahan and Weinberg 2011]. In either scenario, the obstacles 
that need to be overcome by cells forming a neoplasm are complex and vary considerably in 
nature.  
 
1.2.3 Metabolic Supply and Demand 
Unsurprisingly, the regulation of metabolic pathways and biosynthesis also becomes 
dysfunctional in neoplastic disease. Although this trait has been known to be prominent 
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among many types of cancer for decades, the extent to which it has an effect on tumour 
growth dynamics and how it arises is not yet fully understood [Hanahan and Weinberg 
2011]. In normal cells, the primary form of energy metabolism is aerobic respiration. This 
involves the catabolism of glucose (C6H12O6) to pyruvate in the cytoplasm, followed by its 
reduction to CO2 in the mitochondria through the citric acid cycle and electron transport 
chain. This process, known collectively as cellular respiration, can be represented by the 
following chemical equation:  
Respiration:              + 6   → 6    + 6    + ~36    
Clearly, oxygen is a critical reactant for the complete metabolism of glucose. Specifically, it 
is required for the mitochondrial branch of the metabolic network. However, in vivo there is 
an oxygen diffusive limit of roughly 100 μm [Hanahan and Weinberg 2000]. Therefore, as 
cells in an early tumour divide away from the basement membrane (BM), they will approach 
a threshold point where aerobic metabolism is no longer possible. This is compensated for 
by eliminating the dependence on the mitochondria for energy. As a result, the pyruvate 
produced from glycolysis is converted to lactate (C3H5O3
-) and exported from the cell. This 
is in accordance with the following reaction:  
Glycolysis:                    → 2      
  + 2   + 2    
It becomes immediately apparent that the energetic yield is far less for a cell only 
using glycolysis, even when accounting for the oxidative ATP production actually being less 
than 36 in practice. Despite this inefficiency, many cancers have been observed to rely 
predominantly on glycolysis in what is known as the Warburg effect [Casciari et al. 1992, 
(1) 
(2) 
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Vander Heiden et al. 2009]. As with all perturbations to homeostatic cellular processes, an 
inability to return to the steady state can result in survival complications. Thus, cancer cells 
must adapt by multiple means in order to survive and thrive in collaboration with this 
metabolic shift. 
 
1.2.4 The Microenvironment 
A tumour’s surroundings during the stages of development continuously change as a 
result of both intrinsic and extrinsic factors. That is, there exist effects on the 
microenvironment that are produced by the abnormal tissue directly and others which are 
produced indirectly in response to the abnormal tissue surrounding cells. Upon initiation of 
unrestricted growth and division, available nutrients within the microenvironment become 
limiting factors and an inflammatory response may be initiated. Specifically, glucose and 
oxygen are the most prevalent sources of energy for cells in healthy tissues. Once the 
environment progresses to a hypoxic state, the insufficient levels of oxygen result in a 
seemingly inefficient output of energy and dysfunction of the mitochondria. In response to 
this stress, the family of hypoxia-inducible factor (HIF-1) proteins are stabilized and affect 
metabolic pathways to decrease the dependence on oxygen, while also promoting the 
formation of new vasculature. During normoxia, the subunit HIF-1α is rapidly degraded in 
the cytoplasm; however during hypoxia, it is stabilized via ROS and combines with the 
constitutively active HIF-1β to be activated as a transcription factor. Genes that are activated 
as a result of this include enzymes in the glycolytic metabolic pathway, the membrane-
bound glucose transport proteins GLUT-1 and GLUT-3, and also a variety of factors 
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promoting angiogenesis, proliferation and survival [Harris 2002]. Of notable mention is 
lactate dehydrogenase, a protein stabilized by HIF-1 that normally converts pyruvate to 
lactate in the cytosol. As a result, available pools of pyruvate are depleted and other 
mechanisms that prevent aerobic metabolism are amplified. Simultaneously, vascular 
endothelial growth factor (VEGF) is secreted to promote angiogenesis. This ligand activates 
endothelial cells to proliferate and create new vasculature while erythropoietin is expressed 
to activate the production of red blood cells, or erythrocytes, in the bone marrow. These 
effects are made more intricate by the influence of surrounding cells and structural factors. 
As a result, it has been proposed that a tumour should be considered as being comprised of 
both the malignant cells that originate from healthy tissues, as well as cells in the 
surrounding environment that contribute to the growth of a mass [Albini and Sporn 2007]. 
For this reason, an attractive area of research has been targetting the microenvironmental, or 
extrinsic, factors that contribute to the growth of the tumour. 
One of the most prominent environmental cell types that are involved in 
tumourigenesis are pericytes. These cells can be anchored to the BM and have finger-like 
protrusions that span the endothelial cells and allow them to act as both structural promoters 
and growth and survival messengers. For example, they assist in anchoring of the smooth 
muscle cells to the endothelial cells, which provide structural support to counter the pressure 
variations resulting from pulsatile bloodflow. Simultaneously, they provide signalling factors 
like VEGF and platelet-derived growth factor (PDGF) to regulate quiescence or proliferation 
in endothelial cells. Angiogenesis requires the presence of pericytes and so investigating 
their significance has been related to developing novel treatment strategies [Raza et al. 2010, 
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Hanahan and Weinberg 2011]. Examples of other elements in the microenvironment that 
play a critical role are the macrophages, T and B lymphocytes, neutrophils and mast cells. 
They are significant for the inflammatory response that they induce to combat the volatile 
environments that arise during malignant evolution [Hanahan and Weinberg 2011].  During 
normal tissue damage or infection, these cells of the innate immune response are recruited to 
the site of injury and begin releasing critical growth factors, chemokines, and various other 
messenger proteins. The increased heat, redness and swelling at the injury site is indicative 
of fighting an infection, but it also indicates the regeneration of the damaged tissues. The 
immune cells that promote this process have been manipulated in tumourigenesis to favour 
growth, motility, vascularization, and metastasis. Although it may seem confounding how 
the cytotoxic lymphocytes are able to promote growth when their normal function is to 
destroy abnormal cells, it is now believed that they are responsible for the recruitment of 
other lymphocytes whose inflammatory response mechanism may be helpful to the tumour 
[Hanahan and Weinberg 2011]. Interestingly, the macrophages that assist in promoting 
tumour survival are phenotypically distinct from healthy macrophages and can respond 
appropriately to the environment presented [Lewis and Pollard 2006]. During the initial 
inflammatory response, they may first promote mutagenesis and tumour progression through 
increasing ROS. Subsequently, they assist hypoxic regions of the tumour through the 
promotion of vasculature [Qian and Pollard 2010]. While there are many more cells that may 
assist in tumour progression, the last ones discussed are cancer-associated fibroblasts. Their 
particular role is intriguing because of their involvement in maintaining the ECM, a 
collection of various fibrous proteins and carbohydrates that serve structural purposes like 
the basement membrane for epithelial cells , as well as a medium for the transduction of 
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cellular signals [Juliano and Haskill 1993]. Similarly to macrophages, there is a distinct 
cancer-promoting phenotype that is expressed by certain fibroblasts that results in increased 
likelihood of metastasis. In fact, the presence of myofibroblasts, which normally remodel the 
ECM and induce angiogenesis, in the tumour stroma has been associated with a poor 
prognosis for tumours. There exist many types of fibroblasts despite a lack of thorough 
knowledge surrounding their interactions in the tumour microenvironment [Franco, et al. 
2010]. Nonetheless, the crucial role that the microenvironment plays during tumour 
formation has been recognized and has become a target in designing therapies. 
 
1.2.5 Metastasis and Cancer Stem Cells  
A characteristic of carcinomas frequently associated with a poor prognosis is the 
development of tumours at secondary locations through the process known as metastasis. 
After a series of morphological changes to both the cells and the environment, cells from the 
tumour acquire the characteristics of a motile cell and migrate to a secondary site where they 
may begin to divide and differentiate (figure 1.3). This first change that must take place for 
this to occur is collectively known as the epithelial-mesenchymal transition (EMT). During 
this process, cellular composition is remodelled to support the new purpose. For example, 
the filamentous protein vimentin becomes significantly upregulated. As opposed to utilizing 
the conventional structural proteins such as actin and specific collagens, mobile cells use 
vimentin to maintain cellular structure and organization. The reason for this change is 
believed to be vimentin’s high tolerance for mechanical stress, which would be intensified 
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for cells attempting to migrate through the ECM. This cellular remodelling was first 
observed to be instrumental in the developmental stages of growth and also the adult 
response to damaged tissue when morphogenetic changes and differentiation of 
mesenchymal stem cells are frequent and necessary [Weinberg 2007]. Incidentally, this 
connection gave rise to the theory of cancer stem cells, which are a phenotypically distinct 
subset of tumour cells with important properties. Firstly, these cells must be capable of 
initiating the growth of a tumour when transplanted into immunodeficient mice. 
Furthermore, these cells must be able to reproduce the heterogeneity of cell types observed 
in the original tumour [Sampieri and Fodde 2012]. Cells possessing such qualities have now 
been observed to be present in a variety of solid cancers but accurately identifying and 
sorting them is a task complicated by the variety of membrane-bound proteins that may be 
used for their identification and deciphering their individual contribution to cancer 
progression.  
However, the successful colonization of a secondary tumour is not guaranteed by 
initiating EMT or the CSC phenotype alone since there are many obstacles that determine 
the success of an invasive cell in propagating growth. Aside from the cytokines that are 
sufficient to induce dedifferentiation in epithelial cells, many environmental factors have 
been observed to be influential in determining the outcome of a migrating cell. In particular, 
the ECM and BM act as the first impediments by physically restricting the available space 
for cell motility. Although the incorporation of vimentin in the cytoskeleton increases a 
cell’s elasticity and ability to deform, the lack of permeability in the ECM necessitates 
further action for migration. To address this issue, matrix metalloproteinases, among other 
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100µM 
proteases, are secreted and begin disassembling the surrounding infrastructure. Interestingly, 
it has been proposed that certain tumour cells are released into the environment through 
passive mechanisms that result from poor vascular development and high interstitial pressure 
[Bockhorn et al. 2007].  Indeed, poor vascular development has already been associated with 
increased potential for metastasis. The pericytes that assist in developing and maintaining the 
vasculature of a tumour have been implicated in permitting intravasation because of their 
sparse distribution when compared with healthy tissues [Xian et al. 2006, Raza et al. 2010].  
 
 
 
 
 
 
 
 
 
Similarly, macrophages have been observed to promote intravasation and prime 
secondary environments for the colonization of migrating tumour cells, while tumour-
associated fibroblasts have been observed to promote EMT [Cirri and Chiarugi 2012, Qian 
Figure 1.3:  A simplification of the progression from normal epithelial cells to invasive cancerous 
ones. Initially cells form a monolayer adjacent to the basement membrane and blood vessel. As 
the cells progress in the increasingly limiting environment, traits that promote survival become 
more prominent until intravasation and metastasis through the BM may occur.  
100 µm 
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and Pollard 2010]. While the factors leading to extravasation are presumed to be rate-
limiting in vitro, successful colonization events seem to be much less predictable in vivo 
[Chambers and Matrisian 1997, Bockhorn et al. 2007]. Alternatively, when the environment 
is not viable, dormancy is an option chosen by many cells.  
1.3 Reactive Oxygen Species 
Reactive oxygen species have garnered attention for their diverse roles in molecular 
biology that are a result of their high chemical activity in various settings. In particular, high 
levels of ROS act in a toxic manner on the composition of DNA and cell membranes, while 
moderate levels may act as signalling molecules to enhance a proliferative phenotype. Both 
of these effects are mediated by the reactivity induced by the presence of free radicals, which 
are unpaired valence electrons in molecules. By definition, ROS are any molecules 
possessing or capable of inducing the production of free radicals. Their use in metabolic 
processes result in the presence of ROS such as hydroxyl (OH·), superoxide (O2
·-), singlet 
oxygen (O2
*) and H2O2 [Mates and Sanchez-Jimenez 2000, Wiseman and Halliwell 1996]. 
Due to the potential potency of their presence, anti-oxidant mechanisms are utilized by cells 
to mitigate their effect and ultimately determine the redox state of the cell. Much of the 
intracellular ROS produced by cells is in the highly reactive superoxide form; however, it is 
converted to H2O2 with assistance of superoxide dismutases (SOD), as summarized in the  
following chemical reaction:  
2  
·  + 2  
   
 ⎯       +    (3) 
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Once in the less toxic ROS form, radical removal mechanisms such as catalase, 
glutathione peroxidase and peroxiredoxin become effective [Halliwell 2006]. However, the 
reverse process is also possible with the presence of certain minerals like Fe2+ or Cu+. 
Specifically, the Fenton reaction produces hydroxyl radicals from available H2O2 as 
follows:  
     +      →   
   +   · +     
 Although these hydroxyl radicals have short half-life in vivo, they can be induced by 
elevated superoxide levels and are highly reactive with DNA [Mates and Sanchez-Jimenez 
2000, Valko et al. 2007]. The aforementioned antioxidant mechanisms are able to remove 
excess ROS and maintain the redox state of the cell within a viable range. In general, 
catalase and peroxiredoxins both catalyze the formation of water from H2O2, albeit in 
distinct manners [Sun 1990, Valko et al. 2007, Rhee et al. 2001]. In addition to requiring an 
electron donation by thioredoxins to be in an active state, some peroxiredoxins are also 
involved in regulating H2O2 at the cell membrane, whereas catalase mainly operates in 
peroxisomes [Rhee et al. 2001, Woo et al. 2010, Veal et al. 2007]. Glutathione peroxidase 
varies from these two mechanisms in its ability to scavenge radicals from hydroxyl and 
superoxide molecules and not just H2O2 [Sun 1990, Valko et al. 2007]. If, however, the 
antioxidant mechanisms in place are unable to maintain a viable redox state within the cell, 
two possible situations may arise: cell death by apoptosis, or by necrosis. Depending on the 
extent of oxidant damage, a cell will either undergo a compartmentalized and timely 
deconstruction through rapid ATP depletion, or will expand and lyse [Chandra et al. 2000, 
Valko et al. 2007, Zong and Thompson 2006]. In the latter case, an inflammatory response 
(4) 
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and potential damage to surrounding tissues may result. However, there is evidence that the 
inflammatory response may be beneficial to recruiting growth, survival, angiogenic, and 
metastastic factors in cancer [Wiseman and Halliwell 1996, Zong and Thompson 2006, Qian 
and Pollard 2010, Hanahan and Weinberg 2011].  
Although counterintuitive at first, the notion that the harsh environment created by 
ROS in pre-cancerous and cancerous cells contributes to their progression to malignancy has 
gained considerable support. Firstly, there is an obvious effect on tumour progression that 
results from their toxicity. The sensitivity of DNA to damage by ROS incurs a greater 
possibility of mutatgenic events occurring. Thus, if the cell survives as mutations accumulate 
in proto-oncogenes and tumour suppressor genes, increasingly malignant properties may be 
acquired [Storz 2005, Mates and Sanchez-Jimenez 2000, Wartenberg et al. 2003, Wiseman 
and Halliwell 1996]. Notably, this instability has been purported to be a likely cause for the 
acquired drug resistance often observed in advanced tumours [Pelicano et al. 2004]. In 
addition, ROS play diverse roles in signalling pathways governing many aspects of growth, 
division and survival [Veal et al. 2007]. For example, consider the role of peroxiredoxin as a 
tumour suppressor. When it is downregulated or absent, H2O2 is not catalyzed and is able to 
accumulate at the cell membrane. As a result,  RTK pathways such as PDGF and EGF are 
constitutively activated by the available H2O2, which acts as a signalling molecule by 
oxidizing cysteine residues on the proteins [Rhee et al. 2001, Woo et al. 2010, Choi et al. 
2005]. Emerging evidence of low-level ROS as a messenger molecule has been observed in 
advancing cell cycle progression, as well as increasing the survivability of tumours through 
activating protein cascades and pathways [Boonstra and Post 2004, Veal et al. 2007, Storz 
21 
 
2005]. Additionally, transcription factors that promote cancer progression, such as NFκB 
and AP-1, are activated by ROS [Manna et al. 1998, Acharya et al. 2010]. Moreover, the 
hypoxic response, which entails a metabolic switch to glycolysis and the promotion of 
angiogenesis, and metastasis can be influenced by ROS signalling [Shi et al. 2009, Chandel 
et al. 2000, Goyal et al. 2004, Cannito et al. 2008]. While the stabilization of HIF-1 and 
degradation of  aerobic metabolic factors by ROS moderate the hypoxic response, metastasis 
is promoted through stabilizing matrix degrading enzymes and inducing an EMT in the cell 
so that ultimately, the angiogenic growth will further promote successful extravasation [Li et 
al. 2013, Cannito et al. 2008, Wu 2006]. Given the potential opportunities that exist for 
tumour cells to use ROS in optimizing growth, it is not surprising that cancer cells have been 
observed to express higher levels of endogenous ROS when compared to normal cells in 
vitro and in vivo. However, it is important to consider that the redox state and profile of any 
tumour cell is dependent on the cell line, or clonal population, and maturity [Storz 2005, 
Wartenberg et al. 2003]. 
1.4 Vitamin C Therapy 
 Despite being known as a necessary nutrient in maintaining proper health for almost 
a century, the exact therapeutic potential of VC continues to be debated [Bessey and King 
1933]. While its role as an antioxidant and its ability to prevent scurvy were relatively well-
known, Cameron and Pauling investigated its effects as a supplement to cancer treatment 
that would inhibit tumour growth and published promising results [Cameron and Pauling 
1976, Cameron and Pauling 1974]. Subsequently, conflicting results were published by 
researchers at the Mayo Clinic and the debate over the benefits of VC in cancer therapy 
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began [Creagan et al. 1979, Moertel et al. 1985]. It has since been elucidated that the method 
of drug delivery is likely the source of disparity between the results of the studies conducted. 
In particular, intravenous ascorbate was able to induce anti-tumourigenic effects, while oral 
administration did not. Clearly, the biochemistry of VC is critical to understanding how to 
optimize cytotoxic delivery for therapeutic purposes. 
 The biological significance of VC arises from its ability to donate electrons and the 
resulting behaviours have effects that cascade across many aspects of cell and tissue biology. 
Some of these effects include collagen production, assisting to destabilize HIF-1 during 
normoxia, and DNA modifications that regulate gene expression; all of which require active 
forms of iron to be replenished by VC for enzymatic reactions [Verrax and Calderon 2008, 
Du et al. 2012]. Most importantly, both pro-oxidant and antioxidant effects may be attained 
by supplmental VC [Du et al. 2012, Acharya et al. 2010, Wang and Yi 2008]  . The 
realization of either redox role is determined by the concentration of VC, which itself is 
determined exogenously because of the inability of humans to produce it naturally. When 
consumed orally, ascorbate acts as an antioxidant to radical species like superoxide and 
hydroxyl and becomes the ascorbate radical [Padayatty et al. 2003]. This form is unreactive 
and so the radical can be converted back to ascorbate without causing damage [Du et al. 
2012, Chan 1993]. However, the absorption of VC through the gut is tightly regulated and 
limits the plasma concentration to values below 80 µmol/L.  In constrast, intravenously 
administered ascorbate can produce plasma and urine concentrations exceeding 30mmol/L 
[Padayatty et al. 2004, Monti et al. 2012].  
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Figure 1.4: Mechanisms of action of ascorbate. ROS may be produced in the exterior or interior 
of the cell to produce damage. Alternatively, VC could indirectly inhibit cancer progression by 
fortifying the BM or inhibiting the hypoxic response. 
Conventional therapies involving VC have accordingly been concerned with 
determining how to optimize their anti-tumourigenic effects [Du et al. 2012, Duconge et al. 
2008, Gonzalez et al. 2012].  The theoretical strategy behind treatment methods that promote 
ROS damage have been well-studied but the actual mechanism through which VC exerts 
anti-carcinogenic effects has not yet been fully elucidated [Trachootham et al. 2009, 
Acharya  et al. 2010, Wilson et al. 2014]. Specifically, the elevated internal levels of ROS 
 
 render transformed cells more sensitive to further stress and damage by exogenous ROS, 
while the antioxidant machinery in normal cells functions properly to protect the cell 
[Trachootham et al. 2009]. Fortunately, Chen and his colleagues discovered that H2O2 is 
produced as a direct result of pharmacological (i.e., millimolar) plasma concentrations of 
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ascorbate and that this can be lethal to many cell lines when present in a concentration 
greater than 10 mmol/L [Chen, et al. 2007].  
Since high concentrations of antioxidants exist in the blood, H2O2 production is 
limited to tissues where there are multiple proposed mechanisms of cytotoxicity. Firstly, the 
extracellular mechanism proposes that a catalyst such as Fe3+ induces the formation of 
ascorbate radicals, which then donate radicals to oxygen to produce superoxide [Chen et al. 
2007]. Alternatively, intracellular mechanisms have been proposed to contribute to the 
demise of cancerous cells through uptake of VC via GLUT-1 or specific VC transporters 
[Du et al. 2012]. Subsequently, H2O2 may be generated from the VC, or it may stabilize 
factors that contribute to the production of superoxide [Chatterjee et al. 2008]. Chen 
demonstrated that the likely cause of the cell death is H2O2-mediated depletion of ATP, but 
there is potential for anti-tumourigenic effects by VC not directly producing ROS. Such 
effects include the inhibition of the hypoxic response and metastasis through reenforcement 
of the ECM and basement membrane [Wilson et al. 2014]. In any case, the potential health 
risks associated with mega-dose ascorbate therapy are relatively minor in those with 
properly functioning kidneys and without a glucose-6-phosphate-dehydrogenase deficiency 
[Cameron and Campbell 1974, Riordan et al. 2005]. 
1.5 DCA Therapy 
 Similarly to VC, the first medical discovery regarding the significance of DCA was 
not related to its role in cancer. Originally thought to be a hazardous waste produced from 
chlorination processes, DCA has since been used in the treatment of lactic acidosis in 
HIF 
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children and adults [Stacpoole et al. 1998b]. For this reason, thorough investigations into the 
pharmacokinetics of DCA have been conducted and have revealed interesting trends. Firstly, 
the bioavailability, or the fraction of the administered drug that is absorbed into circulation 
unchanged, is nearly 100%  [Stacpoole et al. 1998b]. Furthermore, the decay dynamics have 
been observed to differ from exposure history and among age groups [Stacpoole et al.  
1998a]. While investigating these dynamics, the only toxic side effect observed was 
peripheral neuropathy, which was reversible with treatment arrest[Stacpoole et al. 1998]. 
However, Michelakis and colleagues identified similar mitochondrial dysfunction in cancers 
and discovered that DCA has potential benefits as a cancer treatment [Michelakis et al. 
2008].  
Specifically, it does so by eliminating some of the advantages gained by cells 
exhibiting the Warburg effect. In cancer and during the hypoxic response, mitochondrial 
function is often impaired and pyruvate that was destined for the mitochondria is converted 
to lactate in the cytosol. DCA has been identified for its ability to activate pyruvate 
dehydrogenase kinase (PDK), which in turn restores pyruvate transport and mitochondrial 
polarization [Michelakis et al. 2008]. Through mechanisms not yet fully understood, the 
restoration of mitochondrial function results in increased expression of ROS and p53, while 
also decreasing GLUT-1, HIF-1, and survival factors and altering cytokine signalling factors 
that normally promote survival and pH stress response [Kumar et al. 2012]. Cumulatively, 
these effects have been documented to inhibit the growth of many cancer types  including 
breast, glioblastoma, Non-Hodgkins Lymphoma, pancreatic, and more [Sun et al. 2010, 
Michelakis et al. 2010, Strum et al. 2013, Monti et al. 2012, Wong et al. 2008].  
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Chapter 2 
Hybrid Cellular Automata 
2.1 Modelling Cancer 
 When designing biological experiments, in vitro, in situ, and in vivo models can be 
used to replicate the conditions present in nature in a controlled setting to varying extents. 
While in vivo models provide the most realistic experimental conditions, they tend to be 
more difficult to control and explore parametrically for technological and feasibility reasons 
[Kam et al. 2012]. Therefore, despite providing the most accurate model in which to study a 
disease, in vivo approaches do not always the most insight when studying the complexity of 
cancer. In contrast, in vitro methods provide the potential to investigate genetic and cellular 
events thoroughly and so they are generally more versatile for experimental investigations. 
With this and taking the increased availability of computing power into consideration, in 
silico methods provide a novel method by which results from in vitro experiments may be 
used to theoretically consider effects that may not be feasible under the prescribed 
experimental conditions used previously [Kam et al. 2012, Deisboeck et al. 2009]. However, 
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accurately incorporating more detailed aspects of tumour growth nevertheless requires 
ongoing efforts in developing new analytical and numerical approaches and techniques 
[Alarcon et al. 2004]. 
Modelling the biological processes governing cancer progression is a daunting task 
because of the complexity through which the disease presents itself on a variety of temporal 
and spatial scales, and also because of the variety of model types that may be appropriately 
applied [Ribba et al. 2004, Byrne 2010]. To illustrate, malignant cancer involves the 
disruption to processes at the molecular, cellular, tissue, and organismal levels [Preziosi 
2003]. As a result, changes at the smallest scale, such as mutations or epigenetic changes to 
DNA, influence the overall behaviour of a cell through gene expression and protein 
production. If they are not fatal, such changes could induce proliferative or survival 
advantages in pre-malignant cells that ultimately transform the microenvironment. In turn, 
the microenvironment poses selective pressure on the developing tumour that may affect the 
gene expression profile of invasive cells [Anderson et al. 2007, Smallbone et al. 2007]. The 
resulting disruption to homeostasis and normal tissue function incurs health issues that pose 
a threat to the entire organism, thus creating a disease with interacting effects spanning a 
number of scales (figure 2.1).  
Taking this into consideration, models that are able to encapsulate the multi-scale 
nature of cancer growth are ideal in revealing mechanistic behaviour during carcinogenesis. 
Early models describing tumour growth relied on continuous equations and a moving 
boundary problem to reproduce the growth behaviour of radially symmetrical tumours with 
basic intercellular forces [Greenspan 1972, Ribba et al. 2004]. Unfortunately, these models 
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are not very versatile and are computationally expensive to investigate. While tumour 
models have evolved to include a variety of progression factors and mathematical 
techniques, those which are capable of revealing the underlying behaviour of the biological 
processes driving cancer progression are most applicable in biology [Anderson and Quaranta 
2008, Preziosi 2003].Therefore, a focus will be made herein to models that incorporate 
aspects of cancer progression at the subcellular, cellular, and extracellular (tissue) levels.  
Specifically, hybrid discrete continuum models permit a method of incorporating these 
multiple scales.  Nevertheless, determining the advantages and disadvantages of techniques 
specific to such models is crucial to producing one that optimally encompasses the behaviour 
of the system being considered.  
 
2.2 Hybrid Models 
 Through integrating traditional continuous methods with discrete elements, hybrid 
models of tumour growth can be constructed that are capable of handling growth on multiple 
temporal and spatial scales. These models are often ideal because they can describe complex 
biological behaviour that would otherwise produce a large system of equations requiring 
considerable computational power to solve. However, models such as this often cannot be 
extrapolated beyond the experimental settings used to derive parameter values and so they 
contribute little to revealing underlying mechanisms. Furthermore, the feasibility of 
producing such models operates under the assumption that sufficient experimental evidence 
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and insight has been collected to produce a realistic model [Ermentrout and Edelstein-Keshet 
1993].  
 
 
Explicitly speaking, discrete elements within hybrid models are manifested in the 
activity of and between cells, or possibly groups of cells, that proceed with each time step 
according to predetermined rules. Generally, these rules are simplifications of the actual 
dynamics governing phenotypic progression and metastasis but they can represent an 
accurate portrayal of tumour behaviour when coupled with stochastic elements. 
Simultaneously, continuous methods, such as ordinary or partial differential equations and 
Figure 2.1: Implicated cellular and spatial scales involved in the modelling of cancer.  
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stochastic equations, can be implemented to capture aspects of tumour growth including, but 
not limited to, nutrient gradients and signalling factors.  
Quantifying the rules driving the discrete progression of components in the model 
requires experimental evidence to ensure validity and to derive actual parameter values. In 
previous models, experimental results from multiple tumours grown in different 
environmental conditions have been compiled for this purpose; however, the combined 
properties may give rise to a model that may not actually correspond to any tumour observed 
yet. Additionally, gathering all of the parameter values necessary to describe a tumour may 
not be possible because of limitations imposed by current laboratory assay techniques [Kam 
et al. 2012]. For these reasons, collaboration between mathematicians and the biologists 
conducting research is critical to produce an accurate model capable of providing 
meaningful contributions to oncology. It should be noted that in addition to coordinating the 
design of experiments for preliminary parameter measurements, the refinement of models 
and hypotheses is a necessary step to ensure that the results obtained are realistic or 
verifiable [Byrne 2010]. This can entail comparing the model results to experimentally 
observed results, or comparing them to other models to determine underlying behaviours and 
the strengths and weaknesses associated with each type [Kam et al. 2012]. 
In the mathematical modelling of tumour progression, models may be broadly 
characterized as being descriptive or mechanistic in nature [Anderson and Quaranta 2008]. 
Furthermore, variations in hybrid models are presented in which aspects of carcinogenesis 
can be investigated in simulations. In general, models either tend to be able to manage large 
cell populations with simplified structures, or small populations of cells that are deformable 
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[Rejniak and Anderson 2011]. As a result, the former class of models allows for the 
investigation of the optimal response to treatments in tumours that are clinically-relevant in 
size, while the latter are capable of more thoroughly investigating the intercellular and 
environmental interactions that contribute to tumour growth and invasion. Consequently, 
designing a model that specializes in either application is dependent on how the cellular 
environment and interactions are implemented. Specifically, cells may either be fixed on a 
lattice, or categorized as off-lattice elements. What follows is an overview of some 
techniques that have been previously employed that reveal the benefits and disadvantages 
associated with implementing different hybrid schemes. 
One of the most frequently used hybrid models is the square or cubed lattice HCA. 
As the name implies and as shown in figure 2.2, the tumour cells may occupy each grid site 
and are considered individually in the model. Avascular and vascular tumour growth, 
invasion, and a variety of environmental interactions stemming from available nurtrients, 
and stromal and tissue organization have been modelled with such methods [Dormann and 
Deutsch 2002, Owen et al. 2009, Smallbone et al. 2007, Gatenby et al. 2007, Anderson et al. 
2006, Bankhead III et al. 2007]. Although the majority of models utilize a mutually 
exclusive organizational scheme for grid sites, certain types of models have been expanded 
to include lattices that allow  multiple cells per site or multiple sites per cell in an attempt to 
capture different aspects of tumour progression.  Allowing multiple cells to inhabit a lattice 
site has the advantage of producing larger and more relevant tumour sizes; however, the 
migration of cells becomes difficult to implement efficiently [Rejniak and Anderson 2011]. 
Conversely, representing cells with multiple grid sites provides the advantage of capturing 
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the heterogeneity of cell size through deformations and the resulting influence on cell 
division, invasive advantages, and vasculature formation [Jiang, et al. 2005, Rubenstein and 
Kaufman 2008, Poplawski et al. 2009, Shirinifard et al. 2009]. In particular, the overall cell 
size and shape are the result of stochastic forces that minimize the energy required for 
structural redesign in response to environmental and intracellular cues [Maree et al. 2007]. 
However, this approach is less applicable to more pronounced structural transformations, 
such as EMT. Hexagonal lattices have also been implemented in diversifying the structural 
entities used to construct the environment. Specifically, this allows one to investigate the 
effects of a having a unique local environment for cells (i.e. 6 possible neighbours) on the 
resulting tissue configuration. To this end, glioma cell migration has been reproduced and 
the effect of contact inhibition on the appearance of ductal tumours in situ has been 
investigated [Aubert et al. 2008, Shumate and El-Shenawee 2009]. 
An alternative to the aforementioned class of on-lattice models are the evolutionary 
HCA, which expand upon the simpler HCA by incorporating an artificial neural response 
network. Rather than using pre-determined thresholds or functions to induce cell changes 
such as proliferation, quiescence, or cell death, a network of nodes for each process are 
related to ranges of environmental conditions with varying affinities. Although the resulting 
behaviour of the cells as a tissue can be made to reproduce experimentally observed growth, 
their favourability as a model arises from less deterministic applications [Gerlee and 
Anderson 2007]. Notably, evolutionary HCA models are able to simulate events occurring at 
the genetic level and impose phenotypic changes that affect the overall behaviour of the 
system as a tissue. This is accomplished through adjusting the strength of the connection 
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between the environmental conditions tested and the node decided as outcome (i.e. division, 
quiescence, or death) after division to simulate a mutagenic event. While each mutagenic 
event in the model does not explicitly correspond to a single mutagenic event to DNA, the 
resulting phenotypic changes from these mutations emulate the physical morphology and 
clonal diversity observed to arise in cancers under varying environmental conditions [Gerlee 
and Anderson 2007].  
In contrast to the on-lattice models presented thus far, off-lattice models are effective 
at capturing more realistic spatial configurations through disregarding the uniformly spaced 
grid that has been coupled with continous fields thus far [Rejniak and Anderson 2011]. To 
this end, cells have been implemented as spheres, elipses, tesselated structures, and most 
diversely as fully deformable entities with discretized boundaries capable of replicating 
phenotypic plasticity, polarity, and structural deformation [Ramis-Conde et al. 2008, 
Stolarska et al. 2009, Meineke et al. 2001, Anderson et al. 2007]. However, this versatility 
results in a necessity for more complex algorithms to handle the cellular environment and 
how it maps spatially to the continous fields that are implemented, which are normally 
calculated on a grid similar to those used in on-lattice models [Rejniak and Anderson 2011]. 
 Despite all being capable of spanning multiple scales, each model is best equipped to 
investigate different aspects of tumour progression. For instance, standard HCA’s excel at 
capturing events that effect the overall tissue dynamics, evolutionary HCAs model genetic 
changes and their effect on emerging phenotypes that influence tumour survival, and fully 
deformable cells are able to simulate cellular interactions in an environment that most 
accurately correlates to in vivo conditions [Anderson et al. 2007]. However, each model also 
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has inherent limitations in its ability to capture all dynamics relative to the progression of the 
disease. Thus, in conjunction with whichever aspects of the tumour environment are being 
investigated computationally, the use of multiple distinct models to investigate overlapping 
behaviour can be valuable in determining the underlying mechanistic behaviour that is 
significant for tumourigenesis [Kam et al. 2012]. Although verification of computational 
results by experimental evidence is ideal in determining model validity, cross-examining 
multiple models with unique assumptions can be useful when experimental verification is 
not feasible [Kam et al. 2012]. Due to its relevance in clinical outcomes, the appearance and 
dynamics of invasive phenotypes has been a target for research. For instance, a 
mutlicompartment model incorporating game theory employed by Basanta and colleagues 
demonstrates the cost-benefit relationship of introducing motile phenotypes in tumours with 
a heterogeneous environment [Basanta et al. 2008]. This work correlates with previous work 
by Smallbone that demonstrates heterogeneity in the environment influences the success of 
phenotypes that lead to motility and invasion; specifically, the effect that the distance from 
the blood supply has on nutrient availability, metabolic phenotype, and acidity [Smallbone et 
al. 2007]. Clearly, comparing and compiling evidence from multiple in silico approaches to 
determine the underlying behaviour is a promising approach to determing what patterns are 
significant in deciphering carcinogenesis. 
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2.3 The Applied Model  
 With a particular interest in investigating the effects of ROS, metabolic phenotype, 
and microenvironmental factors on tumour response to treatment, a square-lattice HCA 
model is employed. As with most hybrid models, reaction-diffusion equations model the 
oxygen and glucose fields. In general, these equations produce the following system:  
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Figure 2.2: Select examples of the potential hybrid model types that can be useful in modelling 
cancer. Adapted from [Rejniak and Anderson 2011]. 
(5) 
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(6) 
(7) 
(8) 
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Here, Di is the diffusion coefficient for element i, oxygen or glucose, and ∇ is the 
conventional Laplacian operator. Because each time step in the discrete progression of the 
system is an hour, a steady state approximation can be made that renders the time derivative 
zero and greatly reduces the complexity of solving the system. Similar equations are also 
used for the diffusion of VC and DCA, but they differ in the complexity of consumption 
dynamics. While many models have previously used a constant value for nutrient 
consumption, this fails to encapsulate the dynamic nature of the demand for metabolic 
precursors [Patel et al. 2001, Alarcon et al. 2003, Anderson et al. 2009].  Thus, the following 
functions are introduced for the consumption of oxygen and glucose:  
                                                         (  ,   ) =   
  
     
  (  ) 
  (  ,   ) =    
  
     
  (  ) ,  
where pg is the normoxic consumption of glucose, kG and kO are the Michaelis parameters, 
and r is the ratio of glucose to oxygen consumption. When   = 1, the consumption reflects a 
cell with deficient oxidative machinery; whereas when   = 6, the cell would be using 
oxidative respiration efficiently and exclusively. The functions   (  ) are non-linear and 
were reverse-engineered from experimental data collected from in vivo tumours grown in the 
proximity of a single blood vessel [Molavian et al. 2009]. Overall, consumption obeying 
Michaelis-Menten dynamics was improved upon by including scaling that compensates for 
the effects of metabolic changes that occur in response environmental oxygen and glucose 
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Figure 2.3: Functions determining the consumption dynamics of cancer cells in the 
model [Molavian et al. 2009]. 
(9) 
cues (fi(CO)), as well as the inherent cellular preference (r). The functional form of f is given 
by: 
  (  ) = (1 −     
 .   exp(−100(   − 0.01)
 )) 
where    =
 
 
,    = 1/2, and units are all calculated in 10
-2 mM. As shown in figure 2.3, 
oxygen below a concentration of 4.4 x 10-3 mM corresponds to a hypoxic response in 
metabolism; this presents itself as the glycolytic response and a shift towards independence 
from oxygen. Additionally, an oxygen value below 2 x 10-4 mM represents an anoxic 
environment where the effects of oxygen on metabolism are negligible. 
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(10) 
(13) 
(12)
  
(11) 
 
The model prescribed here incorporates four vessels along the boundary of the lattice 
grid that provide nutrient-rich blood to the environment. However, the permeability of the 
vessel wall and resulting impact on flow across the vessel must be incorporated into the 
boundary conditions. As a result, the flux at the boundary is given by [Patel et al. 2001, 
Alarcon et al. 2003]: 
    ⃗ ∙ ∇   =  (   −   ) 
where   ⃗  is the outward-facing unit vector, µ is the permeability of the vessel wall, Ci is the 
concentration of oxygen or glucose within the stroma, and Cv is the concentration of oxygen 
or glucose within the vessel. 
 In order to solve this system, the following finite difference scheme with step size Δ 
is applied to the interior of the domain for diffusible element l at site (i,j) :  
  
Δ 
     ,  +   ,    +     ,  +   ,    − 4  ,   −      , 
  ,   , 
    = 0 
For any cells sharing a boundary with a vessel wall, which happens to be at location Ci-1,j in 
this case, the following discretization of the boundary condition is imposed [Alarcon et al. 
2003]:  
−
  
 
   ,  −     ,   =      −   ,      
Upon isolating for Ci-1,j and substituting into the discretization scheme, the following is 
derived in order to solve the system: 
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(14) 
    ,  +   ,    +   ,    −  3+
Δ  + Δ   
  
  +
Δ 
  
   = 0 
With the environment modelled, the values that are critical to determine the outcome of each 
cell can be calculated. Firstly, the age of each cell required for division can be found from 
Casciari’s empirical modelling of the effects of the environment on the growth rate of cells. 
The ratio of the cell’s doubling time,   , to the doubling time under optimal conditions (~13 
hours) was fitted to the experimental data using the following expression [Casciara et al. 
1992]: 
                                                                    =  (
  
     
)(
  
     
) 
Other influential factors calculated in the model include the distribution of ECM and 
the diffusion of VC and DCA. The ECM concentration, or     , consists of randomly 
assigned values between 0 and 1 from a uniform distribution. A cell’s ability to occupy a site 
is conditional on the ECM being sufficiently sparse. Alternatively, if the concentration of 
ECM proteins is within a predetermined threshold, there is a fixed probability of the cell 
being able to deform and occupy that site. In contrast, DCA and VC are calculated as 
diffusible entities according to equations similar to equations 5 and 6. In contrast, their 
consumption rate is presumed to be independent and constant. The diffusion coefficients for 
VC and DCA, as well as the permeability coefficients, are approximated and presumed to be 
similar to those for glucose and oxygen (Appendix). Furthermore, each treatment has a 
unique effect on ROS production and cell survival and metabolism. In untreated scenarios, 
the concentration of ROS, CROS, is a fixed proportion,  , of the oxygen consumed. When 
present, DCA causes a fixed increase in the proportion of oxygen converted to ROS during 
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metabolism, while VC is presumed to produce H2O2 independently in the extracellular space. 
The production of H2O2 is linearly related to the concentration of VC so it is easy to 
determine once the diffusion of VC has been calculated [Chen et al. 2007]. However, not all 
of the H2O2 produced will necessarily be internalized by the cell. Antunes and Cadenas 
measured the ratio of extracellular to intracellular H2O2 of cell membranes to be a constant 
value [Antunes and Cadenas 2000]. Thus, only a fixed proportion of the extracellular ROS 
contributes to influencing cellular dynamics. In any case, ROS damage is the primary source 
of toxicity for cells and is most often required for cell death by apoptosis or necrosis to 
occur. When not inducing death, ROS can induce a glycolytic phenotype. 
Using a N x N array, each grid square has dimensions ΔxΔ, where Δ = 20   , to house 
individual cells. As the experiments used by Molavian et al. were conducted on a 2D plane, 
the model is most appropriately applied in two dimensions. The following rules are used to 
determine and dictate the progression of the cells, as summarize in figure 2.5:  
1. Empty grid sites may become occupied if an adjacent cell undergoes division to 
that site. The only exceptions are the grid sites on the boundary that are occupied 
by vascular cells.  
2. Oxygen and glucose are calculated with equations 5 and 6, with empty grid sites 
having a consumption rate of zero, and occupied sites consuming oxygen and 
glucose at a rate of FO and FG, respectively. 
3. Cells occupying a grid site are selected at random to be updated at each time step. 
If a cell is older than the division age calculated from equation 14, it may divide 
into an adjacent cell. Each unoccupied site has an equal probability of housing 
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the new cell provided that it does not have too dense of an ECM. If,     < Ψ   , 
the deformation threshold, a cell may divide freely. Alternatively, if     ∈
 [Ψ   , Ψ   ], the cell has a fixed chance of deforming, PDef. If, however, 
     > Ψ   , the cell cannot divide into that site. 
4. Living cells can be defined as quiescent, glycolytic, or oxidative. Any cell with a 
maturity age greater than 150 hours is considered to be quiescent. The glycolytic 
and oxidative phenotypes are determined by calculating r0 = FO/FG. If    ≥ 4, 
the/ cell is considered oxidative. Otherwise, it is considered to be primarily 
glycolytic.  
5. The amount of ATP produced can be calculated from      =
    
 
+ 2(   −
  
 
), 
where the second term representing energy harnessed from glycolysis. 
6. The intracellular concentration of ROS,     , has a direct effect on both the 
metabolism and survival outcome of the cell. If      >     
   
, the cell will switch 
to a glycolytic metabolism [Shi et al. 2009]. Alternatively, if      >     
    
, the 
cell will undergo necrosis or apoptosis depending on     . However if      >
    
   , necrotic cell death will be chosen independently of ATP levels [Leilli Jr. et 
al. 1998, Chandra et al. 2000, Zong and Thompson 2006]. 
7. If the concentration of oxygen falls below a value,   
   , the cell dies by necrosis. 
Alternatively, if the ATP that is generated is less than     
   , necrosis also occurs. 
Necrotic cells at the core increase in age at each time step, but are not updated 
otherwise. Necrotic cells at the periphery of the tumour are removed randomly 
after a fixed time [Brouckaert et al. 2004]. Alternatively, if     
    ≤      ≤
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    
    
, cells will die by apoptosis and be removed after the next time step [Leist, 
et al. 1997]. 
8. ROS are generated from oxygen that is consumed for respiration in the 
mitochondria. Approximately 1-2% of the oxygen consumed becomes a radical-
inducing or possessing species, and so      =   ∗    [Orrenius 2007]. 
Additionally, hypoxia increases the proportion of oxygen committed to becoming 
ROS (i.e.      >  ) [Goyal et al. 2004].  
9. Ascorbate is administered according to the pharmacokinetic model described 
below. Vitamin C is degraded at a constant rate,      and [    ]  : [    ]    = 7 
[Antunes and Cadenas 2000].  
10. DCA concentrations decay from the time of dose administration in a first-order 
manner. When      >     
   , the metabolic pathway used by the cell will move 
preferentially towards respiration. Specifically,    = 6   and so   = 6. In 
addition to restoring oxidative phosphorylation, cells are also more sensitive to 
ROS-induced death (    
        
<     
    
). For cells that are not under oxidative 
stress or DCA influence,   = 5 [Molavian et al. 2009].   
These rules are programmed to determine the evolution of the system at each time step, but 
the pharmacokinetics of the treatment regimens must be considered carefully so that any 
results obtained replicate in vivo dynamics as closely as possible.  
Riordan’s extensive work in high-dose ascorbate therapy includes a two-
compartment model describing tissue and plasma concentrations in response to intravenous 
administration [Riordan et al. 2000]. It can be described using the following diagram: 
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(15) 
(16) 
 
 
This yields the system of ordinary differential equations:  
                                                    
   
  
=  ( ) +      − (   +   )    ( ) 
                                                    
   
  
=       ( ) −     ( ) 
where CT is the accumulated concentration of VC in all tissues, Cp is the effective plasma 
concentration,    is the plasma volume (assumed constant),  ( ) is the administration 
schedule,    is the excretion rate, and    and    are the rates of blood-plasma and plasma-
blood diffusion, respectively [Riordan et al. 2000].  
In contrast with mega-dose VC therapy, the pharmacokinetics of DCA have been 
studied in greater detail among larger demographics over longer periods of time [Stacpoole 
et al. 1998]. While this research has revealed considerable insight into the toxic effects of 
DCA, the optimal dosing in cancer and its effects in adjuvant therapy have yet to be studied 
in detail. An attempt is made herein to explore the effects of both treatments on malignant 
growth so that the potential therapeutic benefits could be taken advantage of in clinical 
situations. 
Figure 2.4: Schematic representation of the two-compartment model used for 
vitamin C removal  
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Figure 2.5: Flow chart for the square-lattice model applied in simulations 
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Chapter 3 
Simulation Results 
3.1 The Role of the Microenvironment 
 3.1.1. ECM Density and Cell Deformability 
 One of the most obvious factors that may influence the growth of a tumour in this 
model is the extracellular matrix. Specifically, the ability of each cell to divide into vacant 
sites in its neighbourhood is determined by the tolerance and ability to deform. In practice, 
this is a highly variable event that depends on intercellular junctions, surface proteins that 
regulate such processes, and matrix metalloproteinases contributing to a cell’s anchorage and 
resulting mobility in an environment with a dense ECM. To investigate such variables, the 
effects of Ψ    and Ψ    are varied. In all simulations that follow, cell using glycolytic 
metabolism are labelled 1 (blue), oxidative cells are labelled 2 (light blue), necrotic cells 
labelled as 3 (yellow), apoptotic as 4 (orange), and quiescent cells are labelled 5 (red). 
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As evidenced above, the morphology of the tumour is greatly affected by the permeability of 
the ECM. The features of the less permissible ECM resemble the fingering morphology 
observed to be a result of the harsh environmental conditions modelled by Anderson and 
colleagues [Anderson et al. 2009]. Unsurprisingly, this also has an immediate effect on the 
size of the tumour. This can be seen in the plot of total number of living cells for each case 
in figure 3.2, where decreased permeability results in a smaller tumour. 
Figure 3.1: Effects of ECM permeability (Ψ   ) on tumour morphology after 600 hrs. 
Top-left: ψmax=0.96. top-right: ψmax=0.9, bottom-left: ψmax=0.8, bottom-right: ψmax=0.7 
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Figure 3.2: Number of living cells existing after 600 hrs as a result of varying Ψ    
Figure 3.3: Effects of ECM deformable potential (Ψ ) on tumour morphology after 600 hrs. 
Top-left: ψx=0.5, top-right: ψx=0.6, bottom-left: ψx=0.75, bottom-right: ψx=0.7 
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In contrast with the effects of decreasing Ψ   , increasing the deformation potential of cells, 
Ψ , results in a recovery of the radially symmetric morphology observed in cells in an 
environment conducive for growth, as shown in figure 3.3. Unsurprisingly, this also 
increases the potential size of the tumour by increasing the number of available lattice sites 
into which a cell may divide provided deformation is possible. As seen below, this effect 
seems to be more modest than when varying Ψ   . 
 
 
 
 
Figure 3.4: Number of living cells existing after 600 hrs as a result of varying Ψ  
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 3.1.2. Calculating ROS Production 
In addition to the effects of the ECM, the production of ROS has a considerable 
effect on facets of tumour growth like metabolism and cell death. Naturally, the method in 
which ROS are calculated in the model and the resulting effect on tumour growth is of 
interest. To investigate these possibilities, the proportion of and method in which oxygen is 
converted to ROS are varied according to different schemes. Firstly, a fixed increase in  , 
the constant proportion of oxygen converted to ROS, is implemented. In particular,  ∗ =
 
 
 .  
 
 
 
Figure 3.5: Effects of using  ∗ =
 
 
  to calculate endogenous ROS productions. Top-
left: oxygen distribution, top-right: tumour structure, bottom-left: metabolic ratio of 
cells (r), bottom-right: ROS concentration 
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Similarly, an increase in ROS that is directly proportional to the age of the cell is 
implemented. In this case,  ∗ [0.01,0.03], where the value of  ∗ is increased by 25% of   
for each 25hrs that the cell has been alive. In either case, the resulting dynamics of the 
system are not significantly influenced.  
 
 
 
 
 
 
 
 
 
In contrast, more complicated methods of determining each cell’s ROS-producing potential 
can be implemented. In particular, a linear mutation scheme is imposed for ROS production 
in which   is increased after each division in which a stochastically determined mutation 
occurs. This mutation scheme results in a range of ROS production values ranging from 1% 
to 3.5% of the environmental oxygen calculated. Consequently, cells on the periphery of the 
tumour are likely to have an increased relative ROS production; they  
Figure 3.6: Effects of using an age-dependent scheme for   to calculate endogenous 
ROS production 
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Figure 3.7: Effects of using a randomly assigned values for   to calculate endogenous 
ROS production 
Figure 3.8: Effects of using a linear mutation scheme to determine   for calculating 
endogenous ROS production 
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represent cell lines that have collectively had the most opportunities to undergo a mutagenic 
event. Lastly, ROS are calculated through assigning random values of   to cells. Similarly to 
the previous cases, the range of   varies between 1% and 3%. However, the morphological 
and environmental properties remain relatively unchanged in each case. 
As observed experimentally, the effects of ROS can have varying results. In 
particular, an increased ROS concentration that is not sufficiently high so as to induce toxic 
effects on cell growth may instead contribute to the proliferative potential of cancerous cells. 
Clearly, the fixed increase of ROS production has the greatest impact on the resulting size of 
the tumour. As ROS increases, the method of ATP production shifts away from respiration 
and towards glycolysis. As a result, a decrease in the amount of glucose available could 
increase the amount of oxygen available while glucose remains readily available. While the 
in vivo justifications for increased proliferative potential involve activation of signalling 
pathways, the change observed is likely due to a decrease in the maturity age of the cell 
required for division (Eq. 14).  
 
 
 
 
 Figure 3.9: Number of living cells at each time as a result of using each scheme for   
when calculating endogenous ROS production 
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3.2 Mega-Dose VC Therapy 
Previous Phase I studies have investigated the toxicity of VC in doses around 2g/kg 
of body weight, or around 100g on average, thrice weekly to achieve plasma concentrations 
upwards of 30 mM [Monti et al. 2012]. These studies have been undertaken with the 
convention that a plasma concentration of 10mM is sufficient to induce H2O2 production and 
cell death.  
 
 
 
 
 
 
 
 
 
Given the multitude of possibilities regarding schedules with a constant dose that maintain 
concentrations above 10 mM, in silico techniques are particularly attractive to investigate 
such options.  
Figure 3.10: Calculated plasma concentration of VC in the hours following each 
administration schedule.  (–) Schedule 1: 50g/hr x 2 hrs. (o) Schedule 2: 50g/hr x 1hr,then 
25g/hr x 2 hrs. (+) Schedule 3: 50g/hr x1h then 10g/hr x 5hrs. (– - –) Schedule 4: 60g/hr x 
1hr, then 8g/hr x 5hrs. (Δ) Schedule 5: 60g/hr x 1hr, then 40g/hr x 1hr. (∎) Schedule 6: 
70g/hr x 1hr then 30g/hr x 1hr. (*) Schedule 7: 80g/hr x 1hr then 20g/hr x 1hr. 
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3.2.1 Simplified Administration Schedules and Dynamics 
It has already been posited that the administration schedule of VC may be optimized 
by adjusting the rate of drug administration so that the time interval during which VC 
concentrations are above 10 mM is maximized rather than the peak VC concentration 
[Gonzalez et al. 2012]. To investigate this claim in the model, a dose of 100g was applied at 
various rates.  
 
 
In this example, the effect of necrotic cell death is particularly evident. Once cells on 
the periphery of the tumour are exposed to high-concentration VC, they become necrotic. 
Since these cells are not removed in the simulation, they present a physical barrier that 
inhibits the space available for cell division. As a result, the tumours exposed to necrosis-
inducing VC concentrations shrink and are unable to expand further (figure 3.11). 
Figure 3.11: Number of living cells at each time as a result of using simplified growth 
dynamics and numerous administration schedules. 
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Furthermore, each treatment with VC is either implemented to induce a constant 
concentration for 1 hour, or 5 hours before being removed immediately; thus, this is a 
general approximation of the pharmacokinetics modelled by Riordan. It is important to note 
that in vivo tumour growth would most likely allow for the pushing of cells from the interior 
outwards, thus negating the effect of the peripheral necrotic ring. These effects on tumour 
growth are investigated in more detail below. 
 
 
 
 
 
 
 
Figure 3.12: Effects of the simplified, low concentration VC treatment on tumour 
dynamics. 
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As demonstrated in these two examples of the various simplified treatment protocols 
presented, the increased proportion of necrotic cells imposes a limit on the potential tumour 
size by encapsulating most of the cells. Whereas growth is predominantly inhibited by 
physical restrictions with higher concentrations of VC, lower concentrations could inhibit 
growth to a similar extent when applied over a longer period of time. However, the effects of 
the treatment using 5mM VC are not long-lasting; the rate of growth immediately resumes at 
pace similar to growth before treatment (figure 3.14). In contrast, 11mM VC treatment 
results in a much slower rate of growth upon recovery. At any rate, the necrotic cells would 
normally be removed and degraded over time with the assistance of cells of the immune 
system [Brouckaert et al. 2004]. Thus, it is more appropriate in the context of biological 
Figure 3.13: Effects of the simplified, high concentration VC treatment on tumour 
dynamics. 
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applications to consider these effects in detail so that the merits and disadvantages of each 
treatment strategy can be distinguished. 
 
 
 
 
 
 
 
 
 
3.2.2 Increased Complexity of Treatment Dynamics and Response 
Incorporating the pharmacokinetic models derived by Riordan and colleagues with 
the removal of cells dying by necrosis at the tumour periphery reveals insights into the 
results obtained and their implications. To do so, a constant total dose of 100g of VC is 
administered in each schedule at varying rates. This results in the different concentration 
curves in figure 3.10. The schedules used herein were derived as follows: 
Figure 3.14 : Number of living cells resulting from the simplified VC treatments at each 
time.  
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1. 50g/hr administered over 2 hrs  
2. 50g/hr administered for 1hr, followed by 25g/hr for 2 hrs  
3. 50g/hr administered for 1hr, followed by 10g/hr for 5hrs 
4. 60g/hr administered over 1hr, followed by 8g/hr for 5hrs  
5. 60g/hr administered over 1hr, followed by 40g/hr for 1hr 
6. 70g/hr administered over 1hr, followed by 30g/hr for 1hr 
7. 80g/hr administered over 1hr, followed by 20g/hr for 1hr. 
 
 
 
 
 
 
 
 
 
Figure 3.15: Effect of Schedule 1 VC with relatively high VC consumption. 
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Figure 3.16: Effect of Schedule 1 VC with moderate VC consumption. 
Figure 3.17: Effect of Schedule 1 VC with moderate VC consumption. 
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Firstly, the effects of achieving a maximal VC concentration are investigated using a 
constant infusion of 50g/hr. As one might expect, the rate of consumption of VC,     , will 
have a direct impact on the amount of cell death that occurs. In particular, VC that is 
metabolized or sequestered in its role of promoting collagen formation or the hypoxic 
response is unable to act as a pro-oxidant and will not be effective in anti-tumourigenic 
behaviour. Thus, a greater consumption of VC is likely to have a decreasing effect on cell 
death.  
As demonstrated in figure 3.15, the survival of a tumour in response to VC treatment 
appears dependent on the rate at which VC can be metabolized. Specifically, values of      
greater than 0.1 result in an insufficient production of ROS to promote cell death. Thus, 
tumours that consist of cells capable of metabolizing elevated levels of VC in the 
microenvironment will have a resistance to treatment-induced cell death. Interestingly, 
comparing the metabolic ratio in figures 3.15-3.17, increased VC metabolism is associated 
with a more oxidative phenotype overall. The peaks observed in figure 3.18 for FVC=0.15 
reveal an interesting behaviour. Particularly, there may be a proliferative advantage acquired 
when VC is not cytotoxic. The efficiency at inducing cell death in each simulation is further 
demonstrated by considering the total number of necrotic, apoptotic, and living cells 
presented in figure 3.21. 
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Similarly, the size of the tumour at the time of the treatment appears to affect the efficacy of 
the treatment in removing cancerous cells entirely. While this scenario may not always be 
predictable in clinical situations, the behaviour is nonetheless interesting in determining the 
frequency of doses that is optimal. However, it is important to note that      for the tumour 
undergoing Schedule 3 treatment in figure 3.19 is less than that of tumour undergoing 
Schedule 1 treatment. This is to ensure that we compare tumours that are both responsive to 
treatment. 
 
Figure 3.18: Number of living cells at each time resulting from the simplified Schedule 
1 treatments with varying values of       
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When considering tumours with an identical rate of consumption of VC, the effects of 
tumour size are not as noticeable (figure 3.20). In other words, treating a tumour with 
Schedule 3 when it is smaller in size may not necessarily compensate for the resistive 
characteristics acquired from increased VC consumption. 
 
Figure 3.19: Tumour radius at each time for Schedule 1 (left) and Schedule 2 (right) 
treatments. Schedule 1 is treating a tumour with     = 0.1 and Schedule 2 with     = 0.05 
Figure 3.20: Tumour radius at each time for Schedule 3 treatment;     = 0.1  
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3.2.3 Treatment Resistance  
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Figure 3.21: Total cell death by necrosis and apoptosis and final number of 
living cells after 600 hrs for each VC schedule. 
Figure 3.22: Number of living cells at each time for a VC-resistant cell 
undergoing Schedule 2 treatment. 
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Often in clinical situations, a resistance to treatments arises in progressive cancers 
that is indicative of a poor prognosis. With regards to VC, catalase is the antioxidant enzyme 
purported to infer treatment resistance in cells [Klingelhoeffer et al. 2012]. When the cells 
within the model are capable of surviving high-dose VC, the exogenous ROS can have a 
proliferative effect on the tumour cells. 
  
 
 
 
 
 
 
This is accomplished in the model by increasing the thresholds at which ROS induces cell 
death:     
    and     
    
. Within the context of the model, this is likely attributable to an 
increased availability of oxygen from the glycolytic switch, which in turn lowers the 
maturity age necessary for division. However, this rapid increase in tumour size results in an 
equally rapid increase in the size of necrotic core. Nevertheless, tumour growth within the 
model is hastened by VC treatment when resistance has been acquired by the cells, as 
demonstrated in figures 3.22-3.23. 
Figure 3.23: Number of living cells at each time for a VC-resistant cell 
undergoing Schedule 1 treatment. 
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3.3 DCA Therapy 
 Since the absorption, metabolism, and excretion of DCA vary among different 
demographics, the pharmacokinetics of healthy adults (i.e., not suffering from lactic 
acidosis) are applied. In particular, DCA is removed from the system much more quickly 
following the initial dose (  /  = 1.03hrs) than subsequent doses (  /  = 6.23hrs) where 
trough concentrations of 0.5 mM are maintained between doses. However, detailed treatment 
schedules for how trough concentrations arise would complicate analysis significantly with 
minimal gains, if any. Thus, unless otherwise specified, all doses are presumed to be 
administered to a system that has previously been exposed to DCA.  
Despite the fact that the exact mechanisms that result in cell death are unknown, the 
effects of DCA on cell death in clinical and laboratory settings has been well-observed [Sun 
et al. 2010,Michelakis et al. 2010, Sun et al. 2011]. While an increase in the metabolic ratio 
is to be expected (i.e. an increase in cell respiration), events involving cell death are less 
predictable. Regardless, a treatment regime similar to those utilized in clinical settings is 
applied in our simulations. This correlates with doses between 6.5mg/Kg and 50mg/Kg that 
are able to induce plasma concentrations of upwards of 5mM daily [Michelakis et al. 2010, 
Flavin 2010]. A notable result from the simulations is the precise tumour region that is most 
affected by DCA treatment. Specifically, the hypoxic regions tend to be most affected by the 
cytotoxic effects of DCA (figure 3.25), as has been suspected but not yet verified in tumours 
[Papandreou et al. 2011].  
 
66 
 
 
 
 
 
 
 
 
 
Figure 3.24: DCA dose curves for individuals with and without previous 
exposure to DCA 
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Bearing in mind that the proportion of hypoxic cells will increase with the tumour’s 
size, and hence with the time elapsed before the treatment, the effects of administering the 
dose at multiple times points was investigated. In particular, it is interesting to note that the 
greatest decrease in the number of cells occurs when treatment is administered after 400 
hours (figure 3.26). Regardless, the rate of growth accelerates following each treatment once 
cells have been removed and resources become more available.  
Figure 3.25: Environmental and morphogenic results immediately 
following a DCA treatment at 400h 
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Figure 3.26: Effect of time of dose administration of DCA on number of 
living cells  
Figure 3.27: Environmental and morphogenic results immediately 
following a DCA treatment at 100h 
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Since it has been observed that certain cell lines are more responsive to DCA 
treatment than others, one must be cautious in relating the results obtained from simulations 
to realistic treatment behaviour [Michelakis et al. 2008, Wong et al. 2008]. With these 
considerations, the simulations indicate that the effect of DCA is not significantly moderated 
by the dose applied. In particular, the maximum effect is achieved with a peak concentration 
of 8mM (figure 3.29). This may be attributed to the fact that DCA allows for regulated cell 
death to be reinstated; thus, there is a theoretical saturation point after which all cells are 
consuming oxygen readily and responding to the hypoxic and oxidant death queues 
appropriately. 
Figure 3.28: Environmental and morphogenic results immediately 
following a DCA treatment at 200h 
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Figure 3.29: Effect of plasma concentration of DCA on number of living cells 
 
Figure 3.30 Total cell death by necrosis and apoptosis and final number of living 
cells after 8mM DCA administered at different times 
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3.4 Strategies for Combining Treatments 
Often the studies conducted on VC and DCA have considered the effects of each as 
an adjuvant therapy; VC has been proposed to be more effective for palliative purposes 
during treatments and DCA for increasing the cytotoxicity of other treatments [Monti et al. 
2012, Mastrangelo et al. 2013, Ayyanathan et al. 2012, Gonzalez and Miranda-Massari 
2014]. Regardless, the effects of these treatments together have yet to be studied clinically.  
Common techniques for applying multiple treatments involve concurrent, sequential, 
and adjuvant administration. Whereas concurrent involves simultaneous dosing, adjuvant 
therapy utilizes a staggered approach where a delay is imposed between the first and second 
administrations of the drugs. Sequential dosing involves administering the second dose once 
the first drug has been cleared from the system, or is no longer in significant concentrations. 
When applied together, many of these techniques actually succeed in killing all living cells 
Figure 3.31: Total cell death by necrosis and apoptosis and final number of 
living cells for different Cmax when administered at td=400. 
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in the simulated tumour. For instance, concurrent administration yields the results shown in 
figure 3.32. Schedule 3 VC administration does not appear to have a significant effect on 
eradicating tumour cells, but more interesting is the fact that there is not a significant 
difference in tumour outcome when it is combined with DCA. Similarly, the effects of 
adjuvant administration are most pronounced with Schedules 1 and 7 (figure 3.33). This 
supports the notion that higher concentrations of VC are more effective than prolonged 
lower concentrations, even when the effects of DCA are contributing. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.32:  Concurrent administration of DCA and VC after 400 hrs 
results in tumour eradication, except when schedule 3 is used.  
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The last class of combination therapy that is investigated is sequential administration. The 
ability to inhibit tumour growth seems to mostly affected by the timing of the administration 
of VC. For the schedules where DCA is administered first, it is after 1 week of daily DCA 
infusions that VC will be introduced; this corresponds to 468 steps (hours) into the 
simulation. Alternatively, VC being administered first corresponds to DCA being introduced 
at approximately 432 steps, or hours, into the simulation. 
Figure 3.33:  Adjuvant administration of DCA and VC after 400 hrs 
results in tumour eradication, except when schedule 3 is used.  
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3.5 Concluding Remarks and Future Directions 
 The HCA model applied herein reflects the sensitivity of the growth of a tumour to 
the environmental considerations. In particular, the ECM and means of calculating ROS 
impact the overall growth of the tumour despite being simple approximations. While more 
detailed ECM interactions have been studied elsewhere, the simple distribution utilized in 
this model nevertheless produces interesting and dynamic behaviour in the form of tumour 
size and morphology [Anderson et al. 2009, Zaman et al. 2005]. Furthermore, various 
methods of calculating the endogenous ROS production from the amount of oxygen 
consumed by cells produce similar morphological patterns, yet different rates of growth 
(figure 3.9). Thus, an improvement on the accuracy of the caculated ROS could yield 
Figure 3.34:  Sequential administration of DCA and VC after 300 hrs   
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interesting and unforeseen results. Specifically, this would entail the use of an integrated 
differential equation model for the antioxidant mechanisms employed by cancer cells; i.e., 
catalase, glutathione peroxidase, and peroxiredoxin regulation.  
As demonstrated by the implications of utilizing realistic pharmacokinetic models 
and necrotic cell removal, the model considerations have a signifiant impact on the results 
obtained. In particular, the cytotoxic effects and implications of a necrotic ring were 
exaggerated prior to the model improvements. While over-complicating the model may be 
counter-productive to the meaningfulness of the obtained results, including the effects of 
environmental cells not of epithelial origin could improve the dynamics. In particular, 
including additional phenotypes for macrophages that remove necrotic cells and induce 
inflammation (and hence provide an exogenous source of ROS production), could have an 
impact on the quantitative behaviour of the model. In addition to the more intricate 
antioxidant mechanisms, this can be manifested in the form of a decreased sensitivity to cell 
death and wider range of acceptable ROS levels.  
The model itself demonstrates that schedules that maximize the plasma concentration 
of VC obtained are necessary to induce death. That is, there is no conclusive evidence that 
moderate concentrations of VC over longer periods of time are more effective in treating 
cancer. However, in cell lines that are resistant to H2O2-mediated cell death, VC could 
contribute to the growth of a tumour through reprogramming metabolic machinery.  As 
intravenous VC use continues to be investigated in phase I and II clinical trials, the 
unpromising results that have been seen in advanced and recurring cancers using this 
treatment strategy prompt a more thorough investigation into the pharmacokinetics of 
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vitamin C in various cancer cell lines and in conjunction with other cytotoxic therapies 
[Hoffer et al. 2008, Gonzalez and Miranda-Massari 2014]. Previously observed effects of 
VC appear to show conflicting results for malignant growth, with some studies showing 
cytotoxic effects and others showing enhanced malignancy [Gonzalez and Miranda-Massari 
2014]. Tumours that have responded to treatment with ascorbic acid have indeed shown to 
be completely eradicated, as the results from this model have indicated. However, this is not 
always clinically relevant. To account for the conflicting results observed, the systemic 
saturation hypothesis in addition to catalase over-expression may explain why excessive 
concentrations of plasma VC do not induce a proportional effect on inhibiting tumour 
growth. Specifically, it has been proposed that a chemical mechanism may exist in which 
larger VC concentrations result in an increase of the proportion that is in the oxidatively 
inactive form of dehydroascorbic acid [Gonzalez et al. 2012]. Nevertheless, controlled and 
randomized clinical trials investigating the efficacy of VC with other cancer therapies have 
yet to be published [Gonzalez and Miranda-Massari 2014]. As a result, improving computer 
simulations could prove to be a promising approach in contributing to the investigation of 
multiple treatment scenarios in chemotherapy and radiotherapy [Deisboeck et al. 2009].  
 DCA has been observed to exert differing cytotoxic effects to cell lines in in vitro 
and in vivo experiments. In the in silico model presented, insights into the experimentally 
observed tumour reduction could prove useful in explaining the persistence of cells capable 
of forming metastatic masses [Sun et al. 2010]. In particular, the sensitivity of cells in the 
hypoxic region of the model allow for the survival of cells in the oxidative region, ultimately 
resulting in its failure as an independent therapy.In other words, the inability of DCA to 
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eliminate tumours in this model is supported by the observed shrinkage and subsequent 
persistance of tumours treated with DCA alone [Michelakis et al. 2010, Sun et al. 2011]. 
This further indicates that particular attention should be made in designing clinical trials that 
incorporate alternative therapies. However, hypoxic and quiescent cells may be more 
sensitive because of decreased overall ATP production. Thus, the incorporation of other 
metabolic pathways, like glutaminolysis, may reveal why certain tumours are completely 
unresponsive to DCA treatment.  
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Appendix of Parameter Values 
Parameter Value Reasoning 
DG 1.1x10
-6 cm2/s [Molavian et al. 2009] 
DO 1.46x10
-5 cm2/s [Molavian et al. 2009] 
DDCA 1.1x10
-6 cm2/s Empirical studies have yet to be published so 
this value is approximated 
DAsc 1.1x10
-6 cm2/s Given the similar chemical structure to 
glucose, the diffusion constant is chosen to be 
the same 
µO 3.0x10
-5 cm/s [Molavian et al. 2009] 
µG 3.0x10
-5 cm/s [Molavian et al. 2009] 
µAsc 3.0x10
-5 cm/s Given the similar chemical structure to 
glucose, permeability is chosen to be the same 
µDCA 1.2x10
-4 cm/s Its bioavailability of 100% of the administered 
dose indicates an increased potential for 
absorption across biological barriers 
[Stacpoole 1998b] 
FVC 1x10
-3 mM/s Multiple values are explored, but this one 
produces realistic growth results 
kDCA 5x10
-4 mM/s Empirical studies have yet to be published so 
this value is approximated 
pg 1.9x10
-3 mM/s [Casciari et al. 1992] 
  1.5x10-3 [Orrenius 2007] 
     2.25x10
-3 [Goyal et al. 2004] 
Ψ    0.7 Multiple values explored 
Ψ    0.96 Multiple values explored 
  
    2x10
-7 mM Indicative of an anoxic and uninhabitable 
environment 
    
   
 2.1x10
-3 mM Calculated ROS concentrations that would 
result from an environment with only ¼ of the 
ideal, as determined by [Casciari et al. 1992] 
oxygen levels available 
    
    
 3.0x10
-3 mM Calculated ROS concentrations that would 
result from an environment with only 1/6 of the 
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ideal, as determined by [Casciari et al. 1992], 
oxygen levels available  
     
      1.8x10-2 mM ~30% of the ATP that would be produced in a 
nutrient-saturated environment (consumption 
of pg and po) [Leist et al. 1997, Casciari et al. 
1992] 
ϕ   
     1.29x10-2 mM ~20% of the ATP that  would be produced in a 
nutrient-saturated environment (consumption 
of pg and pg) [Leist et al. 1997, Casciari et al. 
1992] 
    
     3.5x10-3- mM Calculated ROS concentration that would 
result from an environment with only 1/8
 of the 
ideal, as determined by [Casciari et al. 1992], 
oxygen levels available 
    
          4.1x10-5 mM Chosen to be a proportion of the normal 
apoptotic ROS level so that it reflects scenarios 
in which DCA is lethal to cells with ample 
nutrients 
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